Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: methotrexate

Coding Corner Question: Medical Chart Review of an Infliximab Infusion

From the College  |  June 21, 2018

A 73-year-old female established patient with rheuma­toid arthritis affecting multiple joints and with positive rheumatoid factor returns to the office for an infliximab infusion. She denies any fevers, cough, dyspnea or concurrent illness. She has joint pain of 6 on the pain scale. She is on an NSAID, weekly methotrexate subcutaneous injections, folic acid and…

Filed under:Billing/CodingFrom the CollegePractice Support Tagged with:Billing & Codinginfliximab

Creative Online Strategies for Rheumatologists to Track & Assess Emerging Clinical Trial Data

Carina Stanton  |  June 20, 2018

With extensive clinical trial data being published daily, how does a rheumatologist stay up to date on latest breakthroughs? Rheumatologists can leverage multiple online resources to stay informed and apply information to patient care…

Filed under:Education & TrainingProfessional Topics Tagged with:clinical trialsdataEducationonlineonline education

AbbVie’s RA Drug Succeeds in Late Stage Study

Natasha Yetman  |  June 11, 2018

(Reuters)—Abbvie Inc. says its experimental drug met the main goal of halting progression of moderate to severe rheumatoid arthritis (RA) in a late-stage trial. The drug, upadacitinib, was tested as a monotherapy in patients who have not been treated with chemotherapy agent methotrexate. Upadacitinib, which belongs to a class of drugs known as JAK inhibitors,…

Filed under:Drug Updates Tagged with:Rheumatoid Arthritis (RA)upadacitinib

Alendronate May Provide Cardiovascular Benefits; Plus FDA Approves Subcutaneous Tocilizumab

Michele B. Kaufman, PharmD, BCGP  |  May 28, 2018

New research has linked alendronate to reduced cardiovascular death in hip fracture patients…

Filed under:Drug Updates Tagged with:alendronatecardiovascularFDAFractureship fractureJuvenile Arthritis (JIA)polyarticular juvenile idiopathic arthritistocilizumabU.S. Food and Drug Administration (FDA)

Improved Family Planning Counseling Needed

Susan Bernstein  |  May 18, 2018

In the U.S. today, approximately 45% of pregnancies are unintended or unplanned.1 Although this rate is considerably lower than in the past, women with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) or inflammatory myopathies tend to have better pregnancy outcomes if their disease is well controlled when they conceive. In addition, women taking certain medications…

Filed under:Conditions Tagged with:contraceptivecounselingpregnancy

Rheumatology Coding Corner Question: Billing for an Inflectra Infusion

From the College  |  May 17, 2018

A 68-year-old female patient returns to the office for a second round of Inflectra (infliximab-dyyb) infusion for her rheumatoid arthritis with rheumatoid factor of multiple joints without organ or systems involvement. She reports pain, stiffness and swelling in her left and right knees and right elbow and rates the pain at a 9 on a…

Filed under:Billing/CodingFrom the CollegePractice Support Tagged with:Billing & CodingINFLECTRA (infliximab-dyyb)

The Diagnostic View: Assess Your Rheumatology Knowledge

The Diagnostic View: Our Findings

Sunita Paudyal, MD, & Laura B. Herpel, MD  |  May 17, 2018

Click here for the case. Discussion Image 1 demonstrates two nodules in the right lung, one over the lateral costophrenic sulcus (2.4 x1.7 cm, not shown); and another in the middle lobe (3.1 x 2.6 cm), with lobulated and spiculated margins (red arrow). There was no lymphadenopathy or pleural effusion. Of note, a normal chest…

Filed under:Conditions Tagged with:pulmonary nodulespulmonary nodulosisTNF inhibitors

The Diagnostic View: Assess Your Rheumatology Knowledge

The Diagnostic View: Assess Your Rheumatology Knowledge

Sunita Paudyal, MD, & Laura B. Herpel, MD  |  May 17, 2018

Editor’s note: In this occasional feature, we first present a series of images (this page) for your review, and then a brief discussion of the findings and diagnosis. Before you read the discussion, examine these images carefully and draw your own conclusions. History A 39-year-old white woman with a three-year history of seropositive rheumatoid arthritis…

Filed under:Conditions Tagged with:pulmonary nodulespulmonary nodulosisTNF inhibitors

IgG4-Related Kidney Disease: Diagnostics, Manifestations, & More

IgG4-Related Kidney Disease: Diagnostics, Manifestations & More

Despina Michailidou, MD, PhD, & Paul Cohen, MD   |  May 17, 2018

Immunoglobin G4-related disease (IgG4-RD) is a rare fibro-inflammatory disease of unknown etiology that has been recently recognized. It can cause fibro-inflammatory masses in almost every organ of the body and is associated with dense lymphoplasmacytic infiltration of IgG4-postitive plasma cells, storiform fibrosis and elevated levels of serum IgG4.1 IgG4-RD is a systemic disease that may…

Filed under:ConditionsOther Rheumatic Conditions Tagged with:fibroinflammatoryIgG4 related diseaseIgG4-RDkidney disease

FDA Update: Committee Recommends 2 mg Baricitinib Approval; HLH Identified as Serious Adverse Event for Lamotrigine

Michele B. Kaufman, PharmD, BCGP  |  May 8, 2018

The FDA Arthritis Advisory Committee has recommended the approval of 2 mg baricitinib (but not in a 4 mg dose) for treating adults with moderate to severe active RA…

Filed under:Biologics/DMARDsDrug Updates Tagged with:baricitinibFood and Drug Administrationhemophagocytic lymphohistiocytosisHLHlamotrigineU.S. Food and Drug Administration (FDA)

  • « Previous Page
  • 1
  • …
  • 50
  • 51
  • 52
  • 53
  • 54
  • …
  • 106
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences